Best Life Sciences Companies in Schlieren, Switzerland
The 42 best Life Sciences companies in Schlieren, Switzerland in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Neurimmune.
Our analysis of 576 Life Sciences companies
$91.7b in tracked funding; 70% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Life Sciences companies in Schlieren
| # | Company | Disclosed funding | Last round | Employees | Founder | Stage | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | Neurimmune Developer of antibody therapeutics for the treatment neurodegenerative diseases | $180M | 55 mo ago | 82 | Roger Nitsch CEO & President | Series B | 95 patents Therapeutic antibodies/vaccines for transthyretin amyloidosis and musculoskeletal immunotherapy, plus assay tools | — |
| 2 | ImmunOs Therapeutics Developer of immunotherapies for the treatment of cancer and autoimmune diseases | $102M | 23 mo ago | 31 | Christoph Renner Co-Founder & CMO | Series C | 33 patents Engineered HLA fusion proteins targeting CD47‑SIRPA immune checkpoint modulation | — |
| 3 | Memo Therapeutics Developer of antibodies for treating infectious diseases and cancer | $97M | 27 mo ago | 21 | — | Series C | 52 patents Therapeutic antibodies against BK virus and SIGLEC‑9; gene recovery for immunoreceptor engineering | — |
| 4 | Cytos Biotechnology Developer of novel immunotherapies for asthma treatment | $64M | 257 mo ago | 13 | Joost de Bruijn CEO | Deadpooled | 420 patents Nucleic‑acid therapeutics and virus‑like particle delivery platforms for biotech drugs | — |
| 5 | Anjarium Biosciences Developer of next generation non-viral gene therapies | $60M | 59 mo ago | 38 | — | Series A | 63 patents Lipid‑based nanovesicle (hybridosome) platforms for gene and protein therapeutic delivery | — |
| 6 | GlycoEra Developer of biologics for selective degradation of disease-driving extracellular proteins | $49M | 15 mo ago | 29 | — | Series B | 24 patents Glycoengineered biologics for targeted protein degradation and autoimmune antibody neutralization | — |
| 7 | Delenex Antibody therapeutics for oncology and dermatological inflammatory diseases | $41M | 154 mo ago | — | Eric de La Fortelle ex-CEO | Acquired | — | — |
| 8 | LimmaTech Biologics Developing bioconjugate vaccines using glycoengineering and protein glycosylation techniques | $40M | 30 mo ago | 40 | — | Acquired | 37 patents Patents concentrated in chemistry & materials | — |
| 9 | Mabylon Developer of therapeutics for allergies and neurodegenerative diseases | $39M | 12 mo ago | — | Alcide Barberis CEO | Series B | 38 patents Therapeutic antibodies targeting allergens and ASC inflammasome proteins for allergy and inflammation treatment. | — |
| 10 | InSphero Developer of cell based assays for drug screening | $35M | 41 mo ago | 63 | Jan Lichtenberg Chief Executive Officer and Board Member | Series D | 81 patents Microfluidic organ‑on‑a‑chip platforms for disease modeling and specimen cryopreservation | 1 launch |
| 11 | GlycoVaxyn Developer of bioconjugate vaccines to treat a range of bacterial infections | $32M | 209 mo ago | 21 | Michael Wacker Co-Founder | Acquired | 147 patents Engineered microbial glycosylation for polysaccharide‑protein vaccine conjugates | — |
| 12 | Kuros Biosciences Provider of smart solutions for bone disease management | $25M | 47 mo ago | 66 | — | Public | 26 patents Scalable fermentation and virus-like particle packaging of guanine‑rich oligonucleotides for therapeutic use | — |
| 13 | ProteoMediX Developer of next-generation blood test for prostate cancer | $18M | 59 mo ago | 11 | — | Acquired | 16 patents Clinical protein biomarker detection assays integrating proteomic analysis with MRI imaging | — |
| 14 | Biognosys Provider of proteomics service | $9M | 84 mo ago | 71 | — | Acquired | 35 patents Advanced DIA proteomics and drug-target residence-time analysis for precision drug discovery | — |
| 15 | CT Atlantic Cancer therapeutics using humanized monoclonal antibodies | $9M | 211 mo ago | 3 | — | Deadpooled | 18 patents Therapeutic antibodies targeting tumor-associated antigens, notably MAGEA3 cancer vaccines | — |
| 16 | Aeon Scientific Electromagnetic steering tech used for arrhythmia treatment | $8M | 144 mo ago | — | Dominik Bell CEO | Deadpooled | — | — |
| 17 | arcoris bio Developer of nanotechnology reagents and protocols for RNA and protein detection | $8M | 9 mo ago | — | Scott Fraser Co-Founder | Seed | — | — |
| 18 | Elthera Provider of precision medicine for oncology | $3M | 42 mo ago | 5 | Gunther Spohn Co-Founder & CSO | Funding Raised | 11 patents L1CAM-targeted therapeutic molecules for treating hematological malignancies | — |
| 19 | TOPADUR Pharma Drug development company focusing on drug therapies for severe wound healing | $2M | 124 mo ago | 13 | — | Public | 89 patents Dual-acting PDE5 inhibitor/soluble guanylate cyclase activator transdermal cardiovascular therapeutics | — |
| 20 | Avelo Developer of a breath aerosol diagnostic device for respiratory infections | $2M | 47 mo ago | 8 | Tobias Broger Co-Founder | Seed | 6 patents Collecting and analyzing exhaled aerosol particles for respiratory diagnostic testing | 1 partnership |
| 21 | Redbiotec Multiprotein assemblies as prophylactic vaccines against infectious diseases | $2M | 141 mo ago | 12 | Corinne John Co-Founder | Late Stage | 42 patents HSV therapeutic vaccines and recombinant host cell production of casein proteins | — |
| 22 | PharmaBiome Develoeper of microbiome-based live therapeutics to treat intestinal diseases | $2M | 73 mo ago | 10 | Manuel Banz Co-Founder & COO | Seed | 28 patents Therapeutic microbiome modulation using bacterial consortia and related biomarkers | — |
| 23 | Degradable Solutions Portfolio of dental devices | $1M | 212 mo ago | 25 | Kurt Ruffieux Founder & CEO | Acquired | 10 patents Biodegradable, porous bone implant materials for orthopedic repair | — |
Top 12 Life Sciences companies in Schlieren
#1
Series B · Schlieren, Zurich · founded 2015$38.7Mraised▾
Developer of therapeutics for allergies and neurodegenerative diseases. It offers antibody therapies for Peanut allergy, pollen allergy, ALS, neuroinflammation, and Alzheimer's disease.
- Aug 2025Series B$37M
- Sep 2024Grant (prize money)$1.5M
- May 2020Grant (prize money)$55.5K
- Dec 2019Grant (prize money)$55.1K
#2
Series B · Schlieren, Zurich · founded 2020 · 29 employees$49Mraised▾
Developer of biologics for selective degradation of disease-driving extracellular proteins. It focuses on precision therapeutics for autoimmune diseases by targeting circulating proteins, specifically autoantibodies. The company's platform enables rapid, selective, and deep degradation of target proteins without broad immunosuppression. This approach offers an improved safety profile and the potential for earlier disease intervention, which could improve patient quality of life and lower healthcare costs. The platform can target and degrade any circulating extracellular protein of interest, applicable to diseases driven by circulating proteins, such as autoimmune and neurological diseases.
- May 2025Series B$130M
- Jan 2024Series A—
- Nov 2021Series A$49M
#3
Seed · Schlieren, Zurich · founded 2022$7.8Mraised▾
Developer of nanotechnology reagents and protocols for RNA and protein detection. The platform incorporates a nanotechnology-based signal amplification system. This system permits simultaneous multiplex target detection and is multimodal for applications like immunofluorescence and imaging mass cytometry. Designed for ease of use, it requires no specialized laboratory equipment. Scientific researchers in cell biology and genomics can perform accurate, high-throughput biomolecule quantification. This quantification complements other data analysis methods like RNA sequencing.
- Nov 2025Seed$7.8M
#4
Series C · Schlieren, Zurich · founded 2013 · 31 employees$102.5Mraised▾
Developer of immunotherapies for the treatment of cancer and autoimmune diseases. The company has an HLA-based pipeline that includes first-in-class immunotherapies for the treatment of cancer and autoimmune diseases. The Company´s lead product candidate, IOS-1002, is an HLA-based protein that blocks the activation of three different immunosuppressive receptors (also known as checkpoints) on innate and adaptive immune cells
- Sep 2024Series C$11M
- Jun 2022Series B$74M
- Dec 2019Series A$15.2M
- Oct 2018Series A—
#5
Series C · Schlieren, Zurich · founded 2012 · 21 employees$97.2Mraised▾
Developer of antibodies for treating infectious diseases and cancer. The company has developed its proprietary microfluidic single-cell molecular cloning and screening technologies for the production of antibodies. The company's lead candidate is used to treat infectious diseases.
- May 2024Series C$22.1M
- Nov 2023Series C$27.5M
- Feb 2022Series B$24.9M
- Dec 2021Grant (prize money)$11.4M
#6
Acquired · Schlieren, Zurich · founded 2015 · 40 employees$40Mraised▾
LimmaTech Biologics is a clinical stage biopharmaceutical company focused on the development and manufacture of bioconjugate vaccines using glycoengineering and protein glycosylation techniques previously developed by GlycoVaxyn and now owned by GSK. The company was founded as a spin-off of GlycoVaxyn, which was acquired by GSK in February 2015 following a two-year collaboration. The proprietary bioconjugation platform is claimed to offer potential solutions to many issues associated with the chemical conjugation process - expanding the range of indications, enabling large scale manufacture at low cost. LimmaTech is developing vaccines exclusively for GSK and actively exploring applications of glycoengineering and protein glycosylation technology in other fields.
- Feb 2024Grant (prize money)$2.2M
- Feb 2024Series A$3M
- Oct 2023Seed—
- Oct 2023Series A$37M
#7
Series B · Schlieren, Zurich · founded 2006 · 82 employees$180Mraised▾
Developer of antibody therapeutics for the treatment of neurodegenerative diseases. It has Reverse Translational Medicine technology platform for developing therapies which include pipeline of human antibody programs targeting CNS indication areas. Its drug pipeline includes antibody candidates for Alzheimer's and Parkinson's, amyotrophic lateral sclerosis, frontotemporal dementia, dementia with Lewy bodies as well as cardiomyopathy and type 2 diabetes.
- Jan 2022Series B$30M
- Oct 2017PE$150M
- Jan 2012Seed$1.9M
#8
Series D · Schlieren, Zurich · founded 2009 · 63 employees$35Mraised▾
Developer of cell-based assays for drug screening. The organotypic biological 3D microtissues and microtissue-based assays for biochemical compounds screening and predictive drug testing applications. It offers human prostate and mammary carcinoma, and rat liver microtissues. The company also provides compound toxicity testing, cell invasion assays, cell-to-cell interaction, cell-to-extracellular matrix interaction services. The company is focused on providing assays for metabolic diseases, oncology, and liver diseases.
- Mar 2023Series D—
- Jun 2020Grant (prize money)$56.2K
- Jan 2020Grant (prize money)$56.1K
- Jun 2018Series C$10M
#9
Public · Schlieren, Zurich · founded 2000 · 66 employees$24.6Mraised▾
Kuros Bioscience is a provider of smart solutions for bone disease management. It has developed solutions to improve patient rehabilitation. It provides a MagnetOs, a unique bone graft with submicron surface topography, that harnesses the power of osteoimmunology to deliver uniform, solid and stable spinal fusions. It has also developed a Fibrin-PTH candidate that delivers targeted and controlled bone formation. It promotes bone formation through the induction of osteoprogenitor cell differentiation, enhancement of osteoblast proliferation and by increasing the lifespan of bone-forming cells. The device is in clinical trial 2A stage & FDA approved.
- Sep 2022Post IPO$6.2M
- Jan 2021Grant (prize money)$490.5K
- Jan 2020Grant (prize money)$488.2K
- Jan 2019Post IPO$16M
#10
Series A · Schlieren, Zurich · founded 2016 · 38 employees$60.4Mraised▾
Developer of next-generation non-viral gene therapies. It is a provider of novel enzymatic DNA synthesis tools and technologies for cell and gene therapy applications. It is developing DNA-based vectors by using proprietary drug delivery technology platform Hybridosome which involved engineering extracellular vesicles and exosomes to deliver drugs.
- Sep 2021Series A$60.4M
#11
Acquired · Schlieren, Zurich · founded 2010 · 11 employees$17.6Mraised▾
Developer of next-generation blood test for prostate cancer. The product Proclarix is a protein-based blood test that measures the concentration of Prostate-Specific Antigen molecules in a blood sample.
- Sep 2021Series B$3.2M
- Aug 2018Series B$5.3M
- Aug 2016Series B$5.1M
- Jan 2015Series B$1.1M
#12
Deadpooled · Schlieren, Zurich · founded 1995 · 13 employees$64.4Mraised▾
Developer of novel immunotherapies for asthma treatment. The company's lead target was an immunomodulator (CYT003) that was targeting asthma. CYT003 is a virus-like particle (VLP) containing an oligonucleotide agonist of toll-like receptor 9 (TLR9).
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Life Sciences coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Biotechnology is moving in Switzerland
A read on the academic research around Biotechnology — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 469 Switzerland-affiliated papers.
- ETH Zurich52
- University of Zurich40
- University of Lausanne34
- Agroscope30
- University of Basel30
- Gene2→9
- Chromatin1→8
- Antibody3→7
- Epitope1→5
- Immune system1→4
- Population2→4
- Antimicrobial1→5
- Context (archaeology)1→4
- Agriculture2→4
Where biotechnology is researched across Switzerland
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.